Histamine H3 and H4 Receptor Ligands Modify Vascular Histamine Levels in Normal and Arthritic Large Blood Vessels In Vivo

Inflammation

Volumn 38, Issue 3, 2015, Pages 949-958

  Kyriakidis, Konstantinos ^a   Zampeli, Evangelia ^a   Palaiologou, Marina ^a   Tiniakos, Dina ^a,b   Tiligada, Ekaterini ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

arthritis; histamine; inflammation; peripheral blood vessels; rat

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; DIMETINDENE; GSK334429; HISTAMINE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE H4 RECEPTOR; UNCLASSIFIED DRUG; 1-((5-CHLORO-1H-INDOL-2-YL)CARBONYL)-4-METHYLPIPERAZINE; 1-(1-METHYLETHYL)-4-((1-(6-(TRIFLUOROMETHYL)-3-PYRIDINYL)-4-PIPERIDINYL)CARBONYL)HEXAHYDRO-1H-1,4-DIAZEPINE; ANTIINFLAMMATORY AGENT; AZEPINE DERIVATIVE; FREUND ADJUVANT; G PROTEIN COUPLED RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE RECEPTOR; HRH4 PROTEIN, RAT; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ABDOMINAL AORTA; ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; EXPERIMENTAL ARTHRITIS; GREAT BLOOD VESSEL; HISTAMINE BLOOD LEVEL; IN VIVO STUDY; INFERIOR CAVA VEIN; MALE; NONHUMAN; PHENOTYPE; RAT; ANIMAL; AORTA; BLOOD; INFLAMMATION; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALIA; RATTUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA; ARTHRITIS, EXPERIMENTAL; AZEPINES; DIMETHINDENE; ENDOTHELIUM; FREUND'S ADJUVANT; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HISTAMINE H3 ANTAGONISTS; INDOLES; INFLAMMATION; MALE; PIPERAZINES; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; RECEPTORS, HISTAMINE H3; VENA CAVA, INFERIOR;

EID: 84925823370     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0057-1     Document Type: Article

References (38)

1. Parsons, M.E., and C.R. Ganellin. 2006. Histamine and its receptors. British Journal of Pharmacology 147(S1): 127–125.
2. Kakavas, S., E. Zampeli, K. Papamichael, B. Delitheos, and E. Tiligada. 2006. The mast cell pathway to inflammation and homeostasis: Pharmacological insights. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 5: 323–324.
3. 4 receptors as novel drug targets. Expert Opinion on Investigational Drugs 18: 1519–1531.
4. Tiligada, E., K. Kyriakidis, P.L. Chazot, and M.B. Passani. 2011. Histamine pharmacology and new CNS drug targets. CNS Neuroscience & Therapeutics 17: 620–628.
5. 4 receptor in immune and inflammatory disorders. British Journal of Pharmacology 157: 24–33.
6. Sasaguri, Y., K.Y. Wang, A. Tanimoto, et al. 2005. Role of histamine produced by bone marrow-derived vascular cells in pathogenesis of atherosclerosis. Circulation Research 96: 974–981.
7. 3 receptor agonist, induces endothelium-dependent vasodilation in rat mesenteric resistance arteries. Biological and Pharmaceutical Bulletin 33: 58–63.
8. 3 receptors—general characterization and their function in the cardiovascular system. Journal of Physiology and Pharmacology 49: 191–211.
9. Martín-Martínez, M.A., C. González-Juanatey, S. Castañeda, et al. 2014. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: Scientific evidence and expert opinion. Seminars in Arthritis and Rheumatism 44: 1–8.
10. 4 receptor in synovial cells from rheumatoid arthritic patients. Biological and Pharmaceutical Bulletin 30: 2217–2220.
11. 4 receptor in human osteoarthritic synovial tissue. Inflammation Research 57(S1): 63–64.
12. 4 receptor mediates inflammation and Th17 responses in preclinical models of arthritis. Annals of the Rheumatic Diseases 73: 600–608.
13. 3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Biochemical Pharmacology 73: 1182–1194.
14. 3 receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain. European Journal of Pharmacology 684: 87–94.
15. Abd-Allah, A.R., S.F. Ahmad, I. Alrashidi, et al. 2014. Involvement of histamine 4 receptor in the pathogenesis and progression of rheumatoid arthritis. International Immunology 26: 325–340.
16. Adlesic, M., M. Verdrengh, M. Bokarewa, L. Dahlberg, S.J. Foster, and A. Tarkowski. 2007. Histamine in rheumatoid arthritis. Scandinavian Journal of Immunology 65: 530–537.
17. 4 receptor antagonist with anti-inflammatory properties. Journal of Pharmacology and Experimental Therapeutics 309: 404–413.
18. 4 receptor antagonist JNJ7777120 induces increases in the histamine content of the rat conjunctiva. Inflammation Research 58: 285–291.
19. 4 receptor mediates chemotaxis and calcium mobilization of mast cells. Journal of Pharmacology and Experimental Therapeutics 305: 1212–1221.
20. Tiligada, E. 2012. Editorial: Is histamine the missing link in chronic inflammation? Journal of Leukocyte Biology 92: 4–6.
21. Fang, Z.Y., J. Fontaine, P. Unger, and G. Berkenboom. 1991. Alterations of the endothelial function of isolated aortae in rats with adjuvant arthritis. Archives Internationales de Pharmacodynamie et de Thérapie 311: 122–130.
22. Inglis, J.J., A. Nissim, D.M. Lees, S.P. Hunt, Y. Chernajovsky, and B.L. Kidd. 2005. The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation. Arthritis Research and Therapy 7: R807–816.
23. 4 receptor antagonist JNJ7777120 in a murine model of acute skin inflammation. Experimental Dermatology 21: 32–37.
24. 4 receptor signalling by JNJ 7777120 analogues. British Journal of Pharmacology 170: 78–88.
25. 4 receptor orthologs: Correlations and discrepancies between distal and proximal readouts. PloS One 8: e73961.
26. Takenaga, M., H. Kawasaki, A. Wada, and T. Eto. 1995. Calcitonin gene-related peptide mediates acetylcholine-induced endothelium-independent vasodilation in mesenteric resistance blood vessels of the rat. Circulation Research 76: 935–941.
27. Tiligada, E., D. Aslanis, A. Delitheos, and D. Varonos. 2000. Changes in histamine content following pharmacologically-induced mast cell degranulation in the rat conjunctiva. Pharmacological Research 41: 667–670.
28. Pusztaszeri, M.P., W. Seelentag, and F.T. Bosman. 2006. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. The Journal of Histochemistry and Cytochemistry 54: 385–395.
29. 1-histamine receptors faster venous circulation. Journal of Cellular and Molecular Medicine 15: 2614–2623.
30. Binstadt, B.A., P.R. Patel, H. Alencar, et al. 2006. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nature Immunology 7: 284–292.
31. Blanchet, M.R., M. Gold, S. Maltby, et al. 2010. Loss of CD34 leads to exacerbated autoimmune arthritis through increased vascular permeability. Journal of Immunology 184: 1292–1299.
32. Tippens, A.S., S.V. Davis, J.R. Hayes, E.C. Bryda, T.L. Green, and C.A. Gruetter. 2004. Detection of histidine decarboxylase in rat aorta and cultured rat aortic smooth muscle cells. Inflammation Research 53: 390–395.
33. Gruetter, C.A., B. Bailey, L. Easterling, and J.L. Szarek. 2002. Release of non-mast cell histamine from rat aorta. Life Sciences 70: 1709–1717.
34. Stegaev, V., A.T. Nies, P. Porola, et al. 2013. Histamine transport and metabolism are deranged in salivary glands in Sjogren’s syndrome. Rheumatology 52: 1599–1608.
35. Saligrama, N., L.K. Case, R. del Rio, R. Noubade, and C. Teuscher. 2013. Systemic lack of canonical histamine receptor signaling results in increased resistance to autoimmune encephalomyelitis. Journal of Immunology 191: 614–622.
36. 4receptor: A novel drug target for immunoregulation and inflammation, ed. H. Stark, 309–32. London: Versita.
37. Krementsov, D.N., E.H. Wall, R.A. Martin, et al. 2013. Histamine h3 receptor integrates peripheral inflammatory signals in the neurogenic control of immune responses and autoimmune disease susceptibility. PloS One 8: e62743.
38. 4receptor: A novel drug target for immunoregulation and inflammation, ed. H. Stark, 333–52. London: Versita.